GBA's "2021 Stock Phantasma"

Discussion in 'Stocks' started by stonedinvestor, Jan 1, 2021.

  1. vanzandt

    vanzandt

    ahahah
    You're a trip Stoney.

    Where's NFLX at lol?

    This is such a bs game.

    To answer my own question.... who cares.

    They're talking about India now. NFLX India.

    Ooooookay.

    "All eyes on NFLX tonight".....
    -cnbc

    Hey Stoney, do you have a picture of your salmon farm operation with all the fish having a hook in their mouth?
    I'm not saying NFLX won't go up or down, but what I am saying is...
    ...whatever
    ... nevermind.
     
    #621     Jan 19, 2021
  2. vanzandt

    vanzandt

    How do we get on those Robinhood forums?

    I promise I won't write intelligently about stocks.

    (Now there's a meatball pitch for our haters here.)
    :rolleyes:
     
    #622     Jan 19, 2021
  3. vanzandt

    vanzandt

    Time to short LAZR Stoney?
    $29.85
    I think she's going lame.
    Who's that Chinese car company you like so much use for Lidar?
    Where do they get their chips?

    When all else fails Stoney... buy Nvidea.

    From 2016 when it was in the low $70s:
    https://www.elitetrader.com/et/threads/nvda.303875/

    $521 today.
     
    #623     Jan 19, 2021
  4. van the answer was right in front of us--- AMTX<------
    AMTX

    Aemetis

    $4.10
    +0.48 (+13.26%)<--- Ok I screwed up. But I buy tomorrow. This and WPRT?

    Why> Biden hired some guy who has an alt fuel stk that went through the roof today GENT? Something like hat..... AMTX is alt fuel!!!
     
    #624     Jan 19, 2021
  5. Chinese EV's

    XPEV-

    Li--

    / / /
    VWAGY

     
    #625     Jan 19, 2021
  6. . AquaBounty Technologies
    Most investors probably haven't heard of AquaBounty Technologies(NASDAQ:AQB), even though its stock more than tripled in 2020. In a nutshell, AquaBounty develops and raises genetically engineered salmon that eat less feedstock and yield more when harvested. So, when the company announced that its very first batch of super-salmon would be harvested before the end of the year,its stock popped in anticipation. In fact, while it spent most of the year as a micro-cap, AquaBounty has grown enough since the end of September to earn the small-cap label.

    Currently, its salmon product is the only genetically engineered animal protein that's approved by regulators for human consumption in the U.S. and Canada. Over the next few years, AquaBounty plans to build new farming facilities in North America while advancing through the regulatory approval process in a handful of international markets. This means that its revenue growth is likely on the verge of accelerating and delivering the company with its first consistent earnings. Investors should take note: The company is shaping up to be a leader in the food market of the future.
     
    #626     Jan 19, 2021
  7. All my life I just wanted to be an " insider " a guy who could be granted a ton of stock or even buy a tone of stock that then goes up alot.


    Simply Wall St
    December 20, 2020
    Even if it's not a huge purchase, we think it was good to see that Richard Huber, the Independent Non-Executive Director of AquaBounty Technologies, Inc.(NASDAQ:AQB) recently shelled out US$65k to buy stock, at US$6.50 per share. That purchase might not be huge but it did increase their holding by 16%.

    AquaBounty Technologies Insider Transactions Over The Last Year
    The insider Randal Kirk made the biggest insider purchase in the last 12 months. That single transaction was for US$10m worth of shares at a price of US$2.50 each.

    Wow. Just wow. Stk is $10.50.
     
    #627     Jan 19, 2021
  8. That cat made over $20 mln dolars....
     
    #628     Jan 19, 2021
  9. I SAW SOMETHING DISGUSTING AND VILE TODAY... SOMETHING I CANNOT EVEN REPRINT.
    These analysts have no idea what they are talking about!

    Good News-!
    --Bicycle Therapeutics price target raised to $58 from $30 at Cantor Fitzgerald 07:16 BCYC Cantor Fitzgerald analyst Alethia Young raised the firm's price target on Bicycle Therapeutics to $58 from $30 and keeps an Overweight rating on the shares. Following last week's data update, Young increased the firm's probability of success assumption for BT5528 from 10% to 25% and for BT8009 from 20% to 25%, and thinks the PK/PD data for EphA2 suggest the Bicycle toxin conjugate platform is working as intended. The analyst thinks both programs have blockbuster potential if successful.
     
    #629     Jan 20, 2021
  10. Bad News-- I sold Bicycle last week! Do I get back in???

    --Utz Brands price target raised to $26 from $21 at Citi

    --Logitech price target raised to $120 from $112 at Loop Capital

    --Alibaba's Jack Ma makes first appearance since criticizing China, NYT says

    --Funko price target raised to $14 from $12 at Piper Sandler

    --SenesTech initiated with a Buy at H.C. Wainwright ยป

    --Polaris initiated with an Overweight at Morgan Stanley




     
    #630     Jan 20, 2021